| No. |
DrugBank |
薬物名（臨床試験情報から抽出） |
KEGG DRUG * | KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
| 1 | Azathioprine | 33件: 5-asa, prednisone, azathioprine or remicade; Azathioprine; Azathioprine (aza); Azathioprine (aza) or 6-mercaptopurine (6-mp); Azathioprine 25 mg; Azathioprine and allopurinol; Azathioprine in case of endoscopic recurrence; Azathioprine individualised dose; Azathioprine or 6-mercaptopurine; Azathioprine or adalimumab and infliximab; Azathioprine or mesalazine; Azathioprine or methotrexate; Azathioprine or mycophenolate mofetil; Azathioprine weight-based dose; Azathioprine+enteral nutrition; Azathioprine/prednisone; Combination of protein a immunoadsorption, rituximab, dexamethasone plus azathioprine; Continuation of azathioprine; Corticosteroid and azathioprine; Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Cyclophosphamide-prednisone-azathioprine; Early immunosuppressants (azathioprine, methotrexate); Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate); Infliximab and azathioprine combination at week 0; Infliximab and azathioprine combination at week 14; Infliximab with azathioprine (iifx + aza); Infliximab+azathioprine; Infliximab, azathioprine; Overencapsulated azathioprine (imuran) 50 mg tablet; Prednisone - azathioprine; Products containing azathioprine or 6-mercaptopurine; Rituximab (rtx) and azathioprine (aza); Steroids plus azathioprine; | D00238
D03033 |
- |
- |
18件: 11, 13, 19, 35, 42, 43, 44, 45, 46, 49, 65, 66, 85, 94, 95, 96, 97, 162 |
| 2 | Budesonide | 39件: 0.5 mg budesonide effervescent tablet for orodispersible use; 1 mg budesonide effervescent tablet for orodispersible use; 1mg budesonide effervescent tablet for orodispersible use; 2mg budesonide effervescent tablet for orodispersible use; Budesonide; Budesonide ( zentacort capsules 3mg ); Budesonide (6 mg); Budesonide (9 mg); Budesonide 0.5mg orodispersible tablet twice daily; Budesonide 1mg orodispersible tablet twice daily; Budesonide 6 mg capsules, hard (bux-pvii prototype); Budesonide 9 mg capsules, hard (bux-pv); Budesonide 9 mg capsules, hard (bux-pvii prototype); Budesonide [0.4mg/ml] viscous suspension; Budesonide mmx 6 mg tablet; Budesonide mmx®; Budesonide mmx® 6 mg; Budesonide mmx® 9 mg; Budesonide oral suspension; Budesonide oral suspension [0.2 mg/ml]; Budesonide plus prevacid; Budesonide-formoterol single inhaler; Budesonide-mmx; Budesonide-mmx®; Budesonide-mmx® 6 mg; Budesonide-mmx® 9 mg; Budesonide-mmx™; Budesonide/formoterol; Combination oral budesonide and rectal hydrocortisone; Formoterol/budesonide; High dose of budesonide; Inhaled/swallowed budesonide; Methylprednisolone or budesonide; Oral budesonide; Oral budesonide suspension (mb-9); Oral budesonide suspension (obs); Oral viscous budesonide; Oral viscous budesonide (ovb); Viscous/swallowed budesonide; | D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
10件: 66, 85, 93, 94, 95, 96, 97, 98, 228, 299 |
| 3 | Calcium | 25件: Amorphous calcium carbonate; Ascal(r) / carbasalate calcium; Atorvastatin calcium; Calcitriol & calcium; Calcium; Calcium and cholecalciferol; Calcium carbonate; Calcium carbonate and alphacalcidol; Calcium channel blockers; Calcium channel blockers (amlodipine, azelnidipine); Calcium citrate; Calcium citrate with vitamin d2; Calcium gluconate; Calcium lactate; Calcium levofolinate; Calcium rosuvastatin; Calcium, dietary; Carbasalate calcium; Crestor tablets (calcium rosuvastatin) film-coated tablets; Crystalline calcium supplements; Ibandronate+alfacalcidol+calcium; Low molecular weight heparin calcium injection; Rosuvastatin calcium; Symptomatic treatment (converting enzyme inhibitor, angiotensin ii, anti-renin, aldosterone antagonist diuretic, beta blocker, calcium inhibitor, statin); Vidofludimus calcium; | - |
- |
- |
24件: 6, 13, 19, 46, 49, 51, 65, 68, 75, 79, 84, 93, 94, 95, 96, 97, 214, 215, 222, 224, 235, 265, 298, 299 |
| 4 | Cannabidiol | 6件: Cannabidiol; Cannabidiol (cbd); Cannabidiol / dronabinol capsule 5 mg+2,5 mg; Cannabidiol capsule 5 mg; Cannabidiol oral solution; Cannabidiol tablet 10 mg; | D10915 |
2件: CNR1, CNR2 |
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
14件: 2, 6, 13, 46, 95, 96, 97, 140, 144, 145, 157, 158, 193, 271 |
| 5 | Chloroquine | 4件: Chloroquine; Chloroquine diphosphate; Chloroquine diphosphate 250mg; Hydroxychloroquine or chloroquine; | D02125
D02366
D03469 |
- |
- |
4件: 46, 49, 95, 130 |
| 6 | Ciclosporin | 4件: Aerolised liposomal ciclosporin a; Ciclosporin; Ciclosporin (ciclosporinium); Ciclosporin a; | D00184 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
| 7 | Denosumab | 4件: Denosumab; Denosumab - immunoglobulin g2 human monoclonal antibody to rank ligand; Pralia 60 mg subcutaneous injection syringe(denosumab); Pralia 60mg subcutaneous injection syringe(denosumab); | D03684 |
1件: TNFSF11 |
7件: Breast cancer, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis |
7件: 46, 50, 93, 95, 96, 274, 299 |
| 8 | Efalizumab | 1件: Efalizumab; | D03959 |
1件: ITGAL |
11件: Cell adhesion molecules (CAMs), Epstein-Barr virus infection, Human T-cell leukemia virus 1 infection, Leukocyte transendothelial migration, Malaria, Natural killer cell mediated cytotoxicity, Rap1 signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Staphylococcus aureus infection, Viral myocarditis |
9件: 11, 13, 37, 46, 49, 53, 61, 95, 96 |
| 9 | Erythropoietin | 4件: Erythropoietin; Erythropoietin human recombinant (eporh); Recombinant human erythropoietin; Recombinant human erythropoietin(rhepo); | D03231 |
1件: EPOR |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
9件: 2, 6, 13, 22, 46, 47, 70, 95, 96 |
| 10 | Ethanol | 7件: Andrographis paniculata (ethanol extract); Ethanol; Ethanol (96 per cent); Ethanol 96% gel; Ethanol 98% solution; Ethanol bp; Ethanol gel; | D00068
D02798
D04855
D06542 |
- |
- |
49件: 2, 11, 13, 14, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 58, 61, 63, 64, 65, 66, 81, 84, 85, 86, 88, 95, 96, 97, 113, 145, 162, 164, 222, 224, 228, 251, 279, 280, 283, 284, 285, 288, 298, 299, 300, 331 |
| 11 | Human interleukin-2 | 2件: Human interleukin-2; Recombinant human interleukin-2 (rhil-2); | - |
- |
- |
14件: 2, 13, 35, 46, 49, 51, 55, 56, 63, 65, 95, 96, 97, 271 |
| 12 | Infliximab | 66件: 99m technetium infliximab; 99mtc-infliximab; Abp 710 - biosimilar to infliximab; Adalimumab and infliximab; Adalimumab, etanercept, golimumab or infliximab; Anti tnf therapy including infliximab; Anti-tnf: infliximab (infusion); Azathioprine or adalimumab and infliximab; Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Biosimilar infliximab; Ct-p13 sc (infliximab); Cyclosporine vs infliximab; Inflectra (infliximab); Infliximab; Infliximab (bcd-055); Infliximab (ifx alone); Infliximab (ifx); Infliximab (inf) + mtx, db; Infliximab (remicade); Infliximab (remicade): 100 mg of lyophilized infliximab; Infliximab + methotrexate (mtx); Infliximab 10 mg/kg; Infliximab 20 mg/kg; Infliximab 3 mg/kg; Infliximab 5 mg/kg; Infliximab 5 mg/kg body weight infused over 2 hours; Infliximab 5 mg/kg every 6 weeks; Infliximab 7 mg/kg every 8 weeks; Infliximab [infliximab biosimilar 3]; Infliximab and adalimumab; Infliximab and azathioprine combination at week 0; Infliximab and azathioprine combination at week 14; Infliximab and mtx; Infliximab biosimilar; Infliximab control; Infliximab group; Infliximab increased dose; Infliximab increased frequency; Infliximab infusion; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Infliximab with azathioprine (iifx + aza); Infliximab+azathioprine; Infliximab, adalimumab, certolizumab pegol; Infliximab, azathioprine; Infliximab, etanercept; Infliximab, etanercept, adalimumab; Infliximab, methylprednisolone, methotrexate; Infliximab-biosimilar; Infliximab-eu; Infliximab-innovator; Infliximab-pfizer; Innovator infliximab; Intravitreal infliximab; Methotrexate + infliximab; Remicade (infliximab); Remicade® (infliximab); Remicaide (infliximab); Remsima (infliximab); Response to infliximab associated with methotrexate; Sb2 (infliximab biosimilar); Sb2 (proposed biosimilar to infliximab); Ta-650 (infliximab); Tnf blockers (infliximab, adalimumab, etanercept); Topical infliximab; Trexan+salazopyrin+oxiklorin+prednisolone + infliximab; Tumor necrosis factor inhibitor (etanercept, infliximab, adalimumab, and golimumab); | D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
| 13 | Metronidazole | 6件: 10% metronidazole ointment; Amoxicillin, metronidazole and tetracycline; Azithromycin + metronidazole; Metronidazole; Metronidazole capsule 50 mg; Takecab tablets + amoxicillin + clarithromycin (first-line eradication) takecab tablets + amoxicillin + metronidazole (second-line eradication); | D00409
D05016
D05017 |
- |
- |
8件: 46, 51, 63, 94, 95, 96, 97, 291 |
| 14 | Minodronic acid | 1件: Minodronic acid; | - |
- |
- |
4件: 6, 46, 93, 95 |
| 15 | Mycophenolate mofetil | 17件: Azathioprine or mycophenolate mofetil; Cellcept (mycophenolate mofetil); Cyclosporine combine with mycophenolate mofetil; Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate); Mycophenolate mofetil; Mycophenolate mofetil (cellcept); Mycophenolate mofetil (mmf); Mycophenolate mofetil (mmf) 3 g/day; Mycophenolate mofetil 2 g/day; Mycophenolate mofetil [cellcept]; Mycophenolate mofetil orally 1000 mg twice a day (bid); Mycophenolate mofetil plus lower dose of prednisone; Mycophenolate mofetil(mmf); Mycophenolate mofetil, low dose steroid; Mycophenolate mofetil,methotrexate; Prednisolone and mycophenolate mofetil; Prednisone and mycophenolate mofetil; | D00752
D05094
D05095 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
32件: 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 85, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
| 16 | Mycophenolic acid | 2件: Mycophenolic acid; Mycophenolic acid mofetil; | D05096 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
34件: 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 84, 85, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 |
| 17 | Prednisolone | 46件: Azd4017 and prednisolone; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Corticosteroid (prednisolone); Corticosteroid treatment (methylprednisolone or prednisolone); Corticosteroids (prednisone or prednisolone); Etanercept, methotrexate, prednisolone; Glucocorticoid (prednisone or prednisolone); Intravenous methyl prednisolone; Long-circulating liposomal prednisolone; Low dose prednisolone; Medium dose prednisolone; Methotrexate - etanercept - prednisolone arm; Methyl prednisolone; Methylprednisolone or prednisolone; Oral prednisolone; Overencapsulated prednisolone tablets; Paroxetine & prednisolone; Paroxetine hydrochloride 10 & 20 mg and prednisolone 1 mg bp; Peg-liposomal prednisolone sodium phosphate; Prednisolone; Prednisolone & dipyridamole; Prednisolone + mabthera; Prednisolone 1mg tablets; Prednisolone 20 mg; Prednisolone 40 mg; Prednisolone 5 mg; Prednisolone 5mg tablet; Prednisolone acetate; Prednisolone and chlorambucil; Prednisolone and mycophenolate mofetil; Prednisolone and taper; Prednisolone sodium metasulphobenzoate; Prednisolone sodium phosphate; Prednisolone sodium succinate; Prednisolone tablets b.p. 5mg; Prednisolone tablets bp; Prednisolone tablets usp 5 mg; Prednisolone-dipyridamole; Prednisone or prednisolone; Prednisone/prednisolone; Pyridoxine plus prednisolone; Soluble prednisolone tablets; Sulphasalazine + hydroxychloroquine or prednisolone; Trexan+salazopyrin+oxiklorin+prednisolone; Trexan+salazopyrin+oxiklorin+prednisolone + infliximab; Z102 (prednisolone and dipyridamole).; | D00472
D00980
D00981
D00982
D01239
D01998
D02156
D03301 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
38件: 11, 13, 25, 26, 35, 38, 39, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 |
| 18 | Prednisone | 57件: 0 mg prednisone; 5 mg prednisone; 5-aminosalicylic acid(5-asa) and/or prednisone; 5-asa, prednisone, azathioprine or remicade; Azathioprine/prednisone; Chinese herb prescription granule plus prednisone; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Corticosteroids (prednisone or prednisolone); Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Cyclophosphamide-prednisone-azathioprine; Glucocorticoid (prednisone or prednisolone); Granulocyte-colony stimulating factor (g-csf) and prednisone; Hormone (prednisone); Hydroxychloroquine + prednisone; Leflunomide 20 mg+prednisone 0.5mg/kg/d; Methylprednisolone (mp) or prednisone (pred); Mycophenolate mofetil plus lower dose of prednisone; Oral prednisone; Oral prednisone 5mg; Over encapsulated prednisone; Prednisone; Prednisone (and methylprednisolone); Prednisone + inhibace/cozaar; Prednisone - azathioprine; Prednisone 0,5 mg/kg orally on alternate days; Prednisone 15 mg; Prednisone 5 mg; Prednisone 7.5 mg; Prednisone acetate; Prednisone acetate tablets; Prednisone alone; Prednisone and cyclophosphamide; Prednisone and mycophenolate mofetil; Prednisone and ustekinumab treatment; Prednisone arrow 20mg; Prednisone arrow 5 mg; Prednisone capsules; Prednisone discontinuation; Prednisone in full dose; Prednisone or prednisolone; Prednisone plus cyclophosphamide; Prednisone tablets usp, 1 mg; Prednisone tablets usp, 2.5 mg; Prednisone tablets usp, 5 mg; Prednisone tablets, usp; Prednisone therapy and pharmacokinetic; Prednisone treatment; Prednisone, cyclophosphamide; Prednisone, fk506, mmf; Prednisone, methylprednisolone,cyclophosphamides; Prednisone/prednisolone; Rayos (delayed-release prednisone); Sotatercept with prednisone boost; Tacrolimus combined with prednisone; Thalidomide, cyclophosphamide and prednisone; Treatment systemic therapy (prednisone); Treatment with systemic therapy (prednisone); | D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
44件: 2, 11, 13, 14, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 95, 96, 97, 113, 145, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 |
| 19 | Risedronic acid | 1件: Risedronic acid; | D00942
D03234
D08484 |
1件: FDPS |
4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
7件: 46, 66, 93, 95, 96, 113, 274 |
| 20 | Tacrolimus | 13件: Busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf; Interferon beta-1b and tacrolimus; Lcp-tacro (tacrolimus); Non-mtx dmards (e.g. sulfasalazine, leflunomide, bucillamine, tacrolimus, or mizoribin); Rectal tacrolimus; Tacrolimus; Tacrolimus (prograf®); Tacrolimus and mmf; Tacrolimus capsule; Tacrolimus capsules; Tacrolimus combined with prednisone; Tacrolimus prolonged-release hard capsules; Tacrolimus with methotrexate; | D00107
D08556 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
30件: 2, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 86, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 228, 283, 284, 299 |
| 21 | Ursodeoxycholic acid | 9件: Udca (ursodeoxycholic acid); Ursodeoxycholic acid; Ursodeoxycholic acid (udca); Ursodeoxycholic acid (urso); Ursodeoxycholic acid 300mg capsule; Ursodeoxycholic acid 300mg tablet; Ursodeoxycholic acid capsules; Ursodeoxycholic acid combination of immunosuppressive agents; Ursodiol (ursodeoxycholic acid, udca); | D00734 |
1件: NR1H4 |
1件: Bile secretion |
12件: 6, 8, 20, 67, 84, 93, 94, 95, 96, 97, 234, 299 |
| 22 | Vitamin D | 16件: 10000iu vitamin d; 19 nor vitamin d; 25oh-vitamin d; 5000iu vitamin d; Alendronate versus alfacalcidol (1-alpha oh vitamin d); High-dose vitamin d (2000 iu per day); Low dose arm receiving neutral oil and 400 iu/g of vitamin d every second day; Standard-dose vitamin d (400iu per day); Verum arm receiving vitamin d oil; Vitamin d; Vitamin d 100ug; Vitamin d 10ug; Vitamin d 25(oh)d; Vitamin d in arm b; Vitamin d oil; Vitamin d powder; | - |
- |
- |
18件: 13, 19, 41, 46, 49, 50, 68, 93, 95, 96, 98, 179, 222, 228, 235, 274, 298, 299 |
| 23 | Zoledronic acid | 4件: Lonafarnib, zoledronic acid, and pravastatin; Zoledronic acid; Zoledronic acid 5mg/bag 100ml inj; Zoledronic acid monohydrate; | D01968
D06378
D06379
D08689 |
1件: FDPS |
4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
11件: 6, 13, 46, 65, 93, 95, 96, 271, 274, 299, 333 |